rEVO Biologics Provides Grant To Yale University To Establish A Center Of Advancement For Preeclampsia

Published: Feb 03, 2015

FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, today announced that it has provided a multi-year grant of up to $1M to Yale University to establish a Center of Advancement to further research and education in preeclampsia, and to uncover and define the best models of clinical care for the condition. rEVO is a biopharmaceutical company focused on the development of treatments for rare diseases, including early onset preeclampsia.

Help employers find you! Check out all the jobs and post your resume.

Back to news